Some 40% of GERD patients taking PPIs see symptoms recur

25 May 2008

Despite daily use of doctor-recommended proton pump inhibitors to control gastroesophageal reflux disease symptoms, nearly 40% of patients who take them continue to experience breakthrough, which is a return of GERD symptoms, such as acid regurgitation and heartburn. These breakthrough symptoms lead more than half of GERD sufferers to use over-the-counter remedies, according to a survey recently conducted by the American Gastroenterological Association Institute.

The study of 1,064 people with GERD found that around 56% of those who experienced breakthrough used an OTC treatment - the majority choosing an antacid - to manage their condition. Furthermore, taking an OTC in addition to a PPI has become routine for these respondents. In fact, more than 70% have been using OTC medications for at least one year.

"The survey results show that people with GERD are not only using their prescribed PPI, but also are turning to over-the-counter remedies as a stop-gap when they have breakthrough symptoms," said John Inadomi, associate professor of medicine at the University of California, San Francisco.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight